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Abstract
Helicobacter pylori  (Hp) is a major human pathogen 
causing chronic, progressive gastric mucosal damage 
and is linked to gastric atrophy and cancer. Hp-positive 
individuals constitute the major reservoir for trans-
mission of infection. There is no ideal treatment for 
Hp. Hp infection is not cured by a single antibiotic, and 
sometimes, a combined treatment with three or more 
antibiotics is ineffective. Atrophic gastritis (AG) is a 
chronic disease whose main features are atrophy and/or 
intestinal metaplasia of the gastric glands, which arise 
from long-standing Hp infection. AG is reportedly linked 
to an increased risk for gastric cancer, particularly when 
extensive intestinal metaplasia is present. Active or past 
Hp infection may be detected by conventional methods 
in about two-thirds of AG patients. By immunoblotting 
of sera against Hp whole-cell protein lysates, a previous 
exposure to Hp infection is detected in all AG patients. 
According to guidelines, AG patients with Hp positivity 
should receive eradication treatment. The goals of treat-
ment are as follows: (1) Cure of infection, resolution of 
inflammation and normalization of gastric functions; (2) 
possible reversal of atrophic and metaplastic changes 
of the gastric mucosa; and (3) prevention of gastric 
cancer. An ideal antibiotic regimen for Hp should achieve 
eradication rates of approximately 90%, and complex 
multidrug regimens are required to reach this goal. 
Amongst the factors associated with treatment failure 
are high bacterial load, high gastric acidity, Hp strain, 
smoking, low compliance, overweight, and increasing 
antibiotic resistance. AG, when involving the corporal 
mucosa, is linked to reduced gastric acid secretion. At a 
non-acidic intra-gastric pH, the efficacy of the common 
treatment regimens combining proton pump inhibitors 
with one or more antibiotics may not be the same as that 
observed in patients with Hp gastritis in an acid-producing 
stomach. Although the efficacy of these therapeutic 
regimens has been thoroughly tested in subjects with Hp 
infection, there is a paucity of evidence in the subgroup 
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of patients with AG. Bismuth-based therapy may be an 
attractive treatment in the specific setting of AG, and 
specific studies on the efficacy of bismuth-based therapies 
are needed in patients with AG. 
Key words: Atrophic gastritis; Preneoplastic condition; 
Intestinal metaplasia; Helicobacter pylori ; Eradication 
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Core tip: Atrophic gastritis (AG) may arise from long-
standing Helicobacter pylori  (Hp) infection and is linked 
to increased gastric cancer risk. According to guidelines, 
Hp-positive AG patients should receive eradication treat-
ment. The goals of treatment are as follows: (1) Cure 
of infection, (2) possible reversal of atrophic/metaplastic 
changes, and (3) prevention of gastric cancer. When 
involving the corporal mucosa, AG is linked to reduced 
acid secretion. At a non-acidic intra-gastric pH, the ef-
ficacy of common treatment regimens may not be the 
same as those observed in an acid-producing stomach. 
There is a paucity of evidence of efficacy of eradication 
regimens in AG patients. Bismuth-based therapies may be 
promising.
Lahner E, Carabotti M, Annibale B. Treatment of Helicobacter 
pylori infection in atrophic gastritis. World J Gastroenterol 2018; 
24(22): 2373-2380  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v24/i22/2373.htm  DOI: http://dx.doi.
org/10.3748/wjg.v24.i22.2373
INTRODUCTION
Helicobacter pylori (Hp), a gram-negative bacterium 
inhabiting the luminal surface of the gastric epithelium 
first isolated in 1982, is thought to have infected humans 
for more than 50000 years. Hp is the most infectious 
human pathogen, affecting approximately 50% of the 
population. In Northern Europe and North America, 
about one-third of adults have this bacterium, whereas in 
Southern and Eastern Europe, South America, and Asia, 
more than half of people are estimated to be infected. 
Hp infection occurs commonly in developing countries, 
whereas the infection rates are decreasing in developed 
countries, potentially indicating that socioeconomic status 
and living standards might play roles in the distribution of 
the infection[1].
As elegantly summarized by De Francesco et al[2], 
there is still no ideal treatment against Hp, and the 
“therapeutic battle” continues, probably for several 
reasons; Hp is a peculiar bacterium characterized by 
some particular features: (1) This organism, notwith-
standing its pathogenic nature, has been present in the 
stomach of humans for many thousands years; (2) it 
is one of the very few bacteria able to survive in acidic 
gastric juice, as it has developed its ecological niche 
between the mucus and the epithelial layer; (3) its chronic 
presence in the human stomach may lead to benign 
and malignant disorders in the upper gastrointestinal 
tract and even to some disorders outside of the gastro-
intestinal tract; (4) although gram-negative, Hp is 
sensitive to penicillin, which generally works better on 
the wall of gram-positive bacteria; (5) Hp infection is not 
cured by a single antibiotic, and sometimes, a combined 
treatment with three or more antibiotics is ineffective; 
and (6) since Hp is able to evade several immune 
defence mechanisms, no effective vaccine has been 
developed. 
Atrophic gastritis (AG) is a chronic disease whose 
main features are atrophy and/or intestinal metaplasia 
of the gastric glands. When the oxyntic mucosa is in-
volved, atrophy leads to a lack of both gastric acid and 
intrinsic factor production as well as to cobalamin or 
iron malabsorption and eventually anaemia[3,4]. AG is a 
complex condition that may arise from long-standing 
Hp infection or in the context of autoimmune gastritis[5], 
and it is reportedly linked to an increased risk for gastric 
neoplasias such as intestinal-type adenocarcinoma and 
type 1 gastric carcinoids, in particular when extensive 
intestinal metaplasia is present[6]. In a meta-analysis, 
the ratios of the AG incidence in Hp-positive patients to 
that in Hp-negative ones ranged from 2.4 to 7.6, with 
a summary estimate of 5 (95%CI: 3.1-8.3)[7], thus sug-
gesting a strong relationship between incidence of AG 
and Hp infection.
Ongoing Hp infection has been linked to an increased 
risk of gastric cancer, though the data are conflicting on 
whether the treatment of Hp infection prevents gastric 
cancer. Hp infection has also been identified as a decisive 
pathogenetic factor of gastric MALT lymphoma, and 
Hp eradication is the treatment of choice in all MALT 
lymphoma patients infected by the bacterium[1,8]. Hp 
has been classified as a class Ⅰ carcinogen by the World 
Health Organization and the International Agency for 
Research on Cancer Consensus Group in 1994[8]. The 
Uemura study on 1526 Japanese subjects showed that 
gastric cancer developed in 2.9% of 1246 Hp-infected 
patients over 7.8 years, whereas gastric cancer was 
not observed in 280 uninfected control subjects or in 
a subgroup of 253 individuals who received Hp eradi-
cation therapy early during follow-up[9]. The greatest 
benefit of cure of Hp infection on gastric cancer risk 
in asymptomatic adults has been reported in regions 
with the highest incidence of gastric cancer; reported 
relative risks for regions of low, intermediate and high 
incidence of gastric cancer were 0.80, 0.49, and 0.45, 
respectively[10]. A recent study of nearly 39000 asymp-
tomatic subjects showed that the cumulative incidence 
of gastric cancer was significantly higher in the non-
eradication group (hazard ratio 4.1) compared to the 
eradication group or to the Hp-negative group[11], thus 
supporting the positive effect of Hp eradication on the 
prevention of gastric cancer in this setting. 
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A meta-analysis found that antral and body gastric 
atrophy could regress after eradicating Hp (pooled OR 
0.5 and 0.2, P < 0.01), but this effect was not observed 
for intestinal metaplasia[12], suggesting that cure of Hp 
infection may have a beneficial long-term effect on 
gastric atrophy. Another meta-analysis reported that 
eradication of H. pylori is effective only in a subset of 
patients in whom intestinal metaplasia or dysplasia are 
absent[13]. Nevertheless, the reported predictors for body 
atrophy reversal were an absence of intestinal metaplasia 
(HR = 2.4, 95%CI: 1.2-4.8), mild atrophy (HR = 2.14, 
95%CI: 1.12-4.1), and moderate-severe inflammation 
before treatment (HR = 5.3; 95%CI: 1.64-17.3)[14]. 
Given the important link between AG and gastric 
cancer, between gastric cancer and Hp infection, and be-
tween Hp infection and AG, the treatment of Hp infection 
in patients with AG is an important issue that we wish to 
focus on in this review.
THE LINK BETWEEN AG AND GASTRIC 
CANCER
AG, especially when associated with intestinal meta-
plasia, is a linked to a higher risk for gastric cancer, thus 
representing a precancerous condition. The eventual 
development of the intestinal-type gastric adenocarcinoma 
is the end result of an inflammation-metaplasia-dysplasia-
carcinoma sequence, the so-called Correa cascade[15]. 
One important determinant of gastric cancer risk is how 
the precancerous changes in the gastric mucosa are 
distributed within the stomach. The oxyntic gland atrophy 
and/or the intestinal metaplasia distributed in a multifocal 
pattern, including the lesser curvature of the corpus and 
fundus (multifocal atrophic gastritis), reported as the 
“extensive” phenotype and has been associated with a 
higher risk of gastric cancer. The idea of ‘gastritis of the 
carcinoma phenotype’ proposes that corpus-predominant 
gastritis increases the risk of gastric cancer[16], probably 
due to changes in the intra-gastric milieu, such as in-
creased pH, reduced ascorbic acid and the scavenging 
of nitrites, perhaps due to dysbiosis of the gastric micro-
biota[17,18] and probably also due to bacteria other than 
Hp, such as Lachnospiraceae, Lactobacillaceae, and 
Streptococcaceae[19].
Notwithstanding a growing body of evidence, the 
composition of a healthy gastric microbiota remains unde-
fined, and the relationship between Hp and other gastric 
bacteria or other microorganisms is yet to be clarified. 
Some evidence shows that Hp decreases the diversity 
of the gastric microbiota, suggesting its predominance 
over other microorganisms. Therefore, Hp may represent 
the main but not the sole microbial trigger of gastric 
diseases, and microbes other than Hp may play a role 
in the occurrence of long-term complications of Hp in-
fection[20]. Therefore, it might be speculated that the 
antibiotic treatment given for eradicating Hp may in 
some cases be beneficial for gastric cancer risk because 
it is efficacious in eliminating bacteria other than Hp.
Previous work tried to quantify the risk of gastric 
neoplasms in AG patients. A progression rate of AG 
to gastric cancer up to 2% yearly has been observed 
at follow-up periods up to 16 years[21,22]. A systematic 
review showed, in AG patients with pernicious anaemia, 
an estimated 7-fold relative risk of gastric cancer[23]. A 
very recent systematic review reported widely ranging 
annual incidence rates of gastric cancer in patients with 
gastric atrophy (0.53 to 15.24 per 1000 person years) 
and intestinal metaplasia (0.38 to 17.08 per 1000 person 
years)[24]. The clinical relevance of AG is supported 
by European guidelines recommending endoscopic-
histologic surveillance with 3-year intervals in patients 
with moderate to severe extensive AG[25]. Similarly, the 
Kyoto guidelines on the management of Hp gastritis 
recommend surveillance of these patients[26].
THE LINK BETWEEN HP INFECTION AND 
AG
AG is viewed as the first important step in the patho-
genesis of gastric cancer, which probably develops in a 
multistep process beginning from chronic gastritis and 
going forward through AG, intestinal metaplasia, and 
dysplasia[15]. It is accepted that this sequence is usually 
triggered by Hp infection and is synergistically influenced 
by a variety of genetic and environmental factors. 
Amongst Hp-positive patients, only up to 2% of subjects 
will develop gastric cancer, supporting the idea that 
the final effects of Hp infection could be affected by its 
prevalence as well as environmental, bacterial, and host 
factors[8,27].
Amongst a prospective cohort of patients with AG 
involving the corporal mucosa, 22.6% and 52.7% of 
patients were Hp-positive as diagnosed, respectively, 
by histology of gastric biopsies and by anti-Hp IgG anti-
bodies assessed by ELISA serology[28]. This result implied 
that there was active or past Hp infection in about two-
thirds of these patients. A further study, investigating 
AG patients for previous exposure to Hp infection by 
immunoblotting of sera against Hp whole-cell protein 
lysates, observed that all the AG patients classified as Hp-
negative by histology and conventional ELISA serology 
showed an immunoblotting seroreactivity, including in 
each case either cagA or vacA[29]; the concomitant sero-
reactivity against cagA and vacA was highly prevalent 
in the Hp-negative AG patients, similar to those with 
positive histologic infection (77.4% vs 86.2%) and with 
positive ELISA serology (vs 61.5%). These data suggest 
that immunoblotting is able to prove a previous exposure 
to Hp infection in virtually all patients with AG, making 
plausible a hidden role of the infection in this condition. 
In clinical practice, the presence of Hp infection in AG 
patients may be difficult to show, as non-invasive tests 
such as the urea breath test or the stool antigen test may 
be falsely negative, and the most reliable test seems to 
be the presence of active infection (acute inflammatory 
infiltration) on histological evaluation of gastric biopsies 
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(OLGIM), may be mentioned[39,40]. In geographical 
areas with a sufficiently high expertise, endoscopic 
scoring systems such as that of Kimura and Takemoto 
can be applied, but histological confirmation is still rec-
ommended[41]. 
The reversibility of AG after Hp eradication remains a 
controversial issue. A recent meta-analysis of 12 studies 
reported that eradication was linked with a significant 
reduction in AG in the corpus (P = 0.006) but not in the 
antrum (P = 0.06); furthermore, there was evidence for 
a significant effect on intestinal metaplasia neither in the 
corpus (P = 0.42) nor in the antrum (P = 0.76)[42]. Two 
other meta-analyses observed consistent findings[12,13], 
showing significant improvement of gastric atrophy 
after cure of Hp infection, whereas improvement was 
not shown for intestinal metaplasia. A very recent long-
term follow-up study reported that AG and intestinal 
metaplasia in the antrum and corpus improved only in 
the Hp-cured patients compared to baseline[43]. These 
data support the idea that Hp eradication may be a pre-
vention strategy for gastric cancer through resolution/
improvement of precancerous lesions. 
PROPOSED ERADICATION REGIMENS
Since the 1990s, in different countries, national and in-
ternational guidelines for the management of patients 
with Hp infection have been published. These guidelines 
generally comprise first-line therapy recommendations, 
which vary by country or region[26,35,44-51]. 
An ideal antibiotic regimen for Hp should achieve 
eradication rates of approximately 90%, and complex 
multidrug regimens are required to reach this goal. 
Amongst factors associated with treatment failure 
are high bacterial load, high gastric acidity, Hp strain, 
smoking, and low compliance. However, the increasing 
antibiotic resistance, particularly against clarithromycin, 
seems to be played a major role in poor outcomes. To 
limit the problem of resistance, a combination of drugs 
with no significant resistance would be necessary[2,35,44]. 
Decreasing eradication rates with standard therapies 
have prompted recent changes in recommended first-
line therapies. Proposed treatment regimens are mainly 
bismuth-based triple therapies in Eastern guidelines, 
mainly concomitant and bismuth-based therapy in West-
ern guidelines, and less commonly sequential or hybrid 
regimens[2]. However, these recommendations refer to 
chronic Hp gastritis, without taking into consideration the 
peculiar condition of AG. 
In particular, AG, when involving the corporal mucosa, 
is notably linked to reduced gastric acid secretion and 
consequent hypochlorhydria. In this particular intra-
gastric microenvironment with a non-acidic intra-gastric 
pH, the efficacy of the common treatment regimens using 
the combination of a proton pump inhibitor with one or 
more antibiotics may not be the same as observed in 
patients with Hp gastritis in an acid-producing stomach. 
Though the efficacy of these therapeutic regimens has 
been largely tested in subjects with Hp infection[52-54], 
combined with Hp IgG serology[30].
As mentioned above, the outcome of Hp infection 
is highly strain- and host-dependent, which implies 
that multiple interplaying factors should be taken into 
consideration[31]. Amongst strain-dependent factors, a 
very recent systematic review showed that Hp strains 
positive for the virulence factors vacA, s1m1, and cagA 
can significantly increase the risk of gastric cancer, and 
these bacterial genetic markers may be used for risk 
stratification between different populations[32].
Corpus-predominant AG is considered one of the 
outcomes of Hp infection that puts patients at higher 
risk for gastric cancer[9]. A previous study using immu-
noproteome technology to identify Hp antigens showed 
that sera from AG (40.5% ± 2%) and gastric cancer 
patients (25.9% ± 1.8%) showed a significantly higher 
and stronger mean immunoreactivity vs Hp antigens 
compared to peptic ulcer patients (11.2% ± 1.3%). 
That method differentially recognized 17 Hp antigens[33]. 
These data suggest that patients with gastric cancer 
and those with AG, its precursor condition, may display 
a common serological immunorecognition pattern of Hp 
antigens, confirming the link between the infection and 
these conditions. 
TREATMENT OF HP INFECTION IN AG
Hp is a major human pathogen causing chronic and 
progressive gastric mucosal damage, and it is aetio-
logically related to gastric atrophy and gastric cancer. 
Hp-positive individuals constitute the major reservoir 
for transmission of the infection[8,34]. According to main 
guidelines and consensus statements[26,35,36], all Hp-
positive individuals should receive eradication treatment 
unless competing considerations are present. This 
recommendation implies that all patients with AG and 
positivity to Hp should receive eradication treatment. 
The possible goals of treatment of Hp infection in AG 
patients are as follows: (1) Cure of infection, resolution 
of related mucosal inflammation and normalization of 
gastric functions (acid secretion); (2) possible reversal of 
atrophic and metaplastic changes of the gastric mucosa 
and preventing the lesions reaching the so-called point 
of no return, beyond which the reversibility of histological 
changes is virtually considered not possible anymore; 
and (3) finally, prevention or risk reduction of gastric 
cancer, as current evidence is consistent with the notion 
that cure of Hp infection may stop the progression 
of damage and may reduce the Hp-related events 
increasing genetic instability in the gastric mucosa[10,37,38].
The potential benefits of cure of Hp infection for 
a single individual, including in terms of cancer risk 
reduction, depend on the degree and extent of atro-
phic damage that has already occurred at the time 
of eradication and the eventual reversibility of that 
damage[26,35]. Amongst the several approaches to stratify 
the risk, the validated histological staging systems, such 
as operative link for gastritis assessment (OLGA) and 
operative link for gastric intestinal metaplasia assessment 
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there is a paucity of evidence in the subgroup of patients 
with AG. From some studies, albeit not designed for this 
aim, eradication rates of AG patients can be extrapolated, 
and they have ranged between 71% and 86%. In a 
previous study in which 192 patients with Hp-positive 
AG were treated with bismuth-based triple regimens, 
an overall eradication rate of 70.8% was achieved[14]. In 
another study, of 57 patients with intestinal metaplasia 
receiving standard triple therapy, the infection was 
successfully cured in 49 patients (eradication rate 
85.9%)[55]. Less recent Japanese studies achieved 
eradication rates of 82.2% and 70.5%[56,57]. Table 1 
summarizes the eradication rates reported in previous 
studies. 
Bismuth-based therapy may be an attractive treat-
ment in the specific setting of AG. Bismuth has been used 
for centuries in medicine. From a gastroenterological 
perspective, bismuth salts have been used to treat 
peptic ulcer disease, dyspepsia, parasitic infections, 
microscopic colitis, and infectious diarrhoea[58]. Soon 
after the discovery of Hp, Marshall highlighted that 
some antimicrobial compounds (e.g., bismuth salts 
and metronidazole) had been used to treat peptic ulcer 
disease in the past with some success. These results led 
to a renewed interest in bismuth compounds, largely 
because bismuth was found to inhibit the growth of Hp 
and effective in eradicating the bacterium[59]. In 1995, 
two articles, independently and at the same time, 
showed that adding PPI to bismuth-based triple therapy 
increased treatment efficacy[60,61]. This combination main-
ly remained a rescue therapy during the following ten 
years, when the PPI-clarithromycin-based triple therapy 
was the standard therapy[62]. Bismuth has an established 
history in the treatment of Hp. Colloidal bismuth sub-
citrate has potent anti-Hp activity (MIC 4-32 μg/mL), 
and in vitro resistance has not been detected. Further, 
bismuth increases eradication when included in double, 
triple, and quadruple regimens[2]. 
In AG patients, in whom acid secretion is generally 
impaired, treatment with PPI may not make sense at 
all. Therefore, in this specific setting, bismuth-based 
therapy may represent a more promising treatment 
option, especially in the recent galenic formulation, 
bismuth subcitrate potassium, metronidazole, and 
tetracycline (BMT, sold under licence as Pylera®). In 
particular, this formula consists of 140 mg of bismuth 
subcitrate potassium (equivalent to Bi2O3), 125 mg of 
metronidazole and 125 mg of tetracycline hydrochloride 
given as a three-in-one capsule four times daily for ten 
days[63]. Generally, this formula is associated with 20 mg 
of omeprazole twice daily, which in hypochlorhydric AG 
patients is not indicated or even useless. One advantage 
of this three-in-one treatment is that it should allow us 
to standardize the doses of molecular antimicrobials, 
which is not always possible when the compounds are 
taken separately. Undeniably, 14 d triple therapy with 
bismuth salts, tetracycline and metronidazole was the 
first therapy to achieve consistently high Hp eradication 
rates[2,63]. The bismuth-based quadruple therapy is in-
cluded among the recommended first-line therapies 
in the current European, United States, Canadian and 
Chinese guidelines[35,36,48,49]. Several studies have inves-
tigated the efficacy of bismuth-containing quadruple 
therapy. A previous systematic review showed that the 
triple capsule Pylera® achieved eradication rates rang-
ing between 84% and 97%. Eradication rates were 
similar for clarithromycin- and metronidazole-resistant 
strains. Eradication rates with an omeprazole, bismuth, 
metronidazole and tetracycline regimen appeared com-
parable between metronidazole-resistant and -sensitive 
strains. This effect was not seen with the use of triple 
therapy in cases of clarithromycin resistance. Previous 
clinical trials did not report any serious side effects from 
bismuth-based regimens, and compliance was similar to 
standard triple therapy[63].
The safety of bismuth administration for Hp eradi-
cation has been confirmed in a systematic review of 35 
randomized clinical trials with a total of 4763 patients, 
2435 of whom were treated with bismuth salts[64]: no 
serious adverse event was reported with the bismuth 
therapy. There was also no statistically significant dif-
ference in the total number of adverse events between 
those receiving bismuth salts and other regimens or in 
the individual adverse events, that is, abdominal pain, 
diarrhoea, dizziness, headache, metallic taste, nausea 
or vomiting. A very recent Italian study compared 10 
d sequential and bismuth-based quadruple therapies 
for first-line Hp treatment in 495 patients, achieving 
similarly high eradication rates (92% vs 91%) as first-
line treatments for Hp infection in clinical practice[65]. 
Unfortunately, patients were not stratified according to 
pattern of gastritis.
Though bismuth salts represent a promising treat-
ment in the setting of AG with a rationale based on 
Reference Countries Patients, n Treatment regimen Cured patients
Sánchez Cuén et al[55], 2016 Mexico 57 Omeprazole (40 mg), amoxicillin (1 g), and clarithromycin (500 mg), 
twice daily for two wk
49 (85.9)
Vannella et al[14], 2011 Italy 192 Dicitrate bismuthate (120 mg qds) for 4 wk, plus amoxicillin (1 g tds), 
and metronidazole (250 mg tds) during the first 2 wk
136 (70.8)
Kamada et al[56], 2003 Japan 45 Omeprazole (20 mg), amoxicillin (1500 mg) and clarithromycin (600 mg) 
for 1 wk
35 (82.2)
Ohkusa et al[57], 2001 Japan 163 Proton-pump inhibitor and antibiotic therapy for 1 wk 115 (70.5)
Table 1  Eradication rates reported in previous studies in patients with corporal atrophic gastritis n  (%)
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the specific pharmacological, bacteriostatic properties 
of bismuth salts, the data on the efficacy and safety 
of bismuth-based regimens without use of PPIs in this 
specific setting are lacking and are urgently needed. 
It should be kept in mind that patients with AG 
have a higher risk for gastric neoplasms and need endo-
scopic surveillance based on the extent and degree 
of these pre-neoplastic mucosal alterations as staged 
by OLGA/OLGIM. This outcome may have a negative 
impact on the quality of life of these patients. A recent 
paper showed that the quality of life (SF-8) scores on 
both the mental component summary and the physical 
component summary significantly improved after 
the eradication of Hp, irrespective of the symptoms, 
especially in patients who had an impaired quality of 
life before the eradication[66]. This improvement may 
represent a further reason to search for and to treat 
Hp infection in the specific setting of patients with AG, 
in whom the timely cure of Hp infection may lead to 
reversal of pre-neoplastic changes, restoration of gastric 
function, and elimination or reduction of gastric cancer 
risk, as schematically illustrated in Figure 1. 
CONCLUSION
In the particular setting of AG, which is generally as-
sociated with a non-acidic intragastric pH, the efficacy 
of the common treatment regimens using proton pump 
inhibitors with one or more antibiotics may not be the 
same as those observed in patients with Hp gastritis in an 
acid-producing stomach. Although the efficacy of these 
therapy regimens has been thoroughly tested in subjects 
with Hp infection, there is a paucity of evidence in the 
subgroup of patients with AG. Bismuth-based therapy 
may be an attractive treatment in the specific setting of 
AG, and specific studies on the efficacy of bismuth-based 
therapies are needed in patients with AG.
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